Source: Pharmacy Times articles
Discontinuing lenalidomide after 3 years of MRD negativity shows low relapse rates in multiple myeloma, offering hope for treatment-free remission.
Recent Content
- What Does Multiple Myeloma Mean?
- FDA Update: Darzalex Faspro Not Approved for Multiple Myeloma
- Temporal genomic dynamics shape clinical trajectory in multiple myeloma
- Bone Marrow Microenvironments Vary Widely in Multiple Myeloma, Study Finds
- Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis
- Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
- Why New Patients With Multiple Myeloma ‘Can Expect Long, Healthy Lives’
- Future Perspectives in Multiple Myeloma
- Patients and Caregivers Aim to Raise Funds for Myeloma Research
- GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series